Sirana Pharma, a biotechnology company focusing on the development of treatments for unmet medical needs in muscle and bone diseases, has entered into a collaborative research agreement with Pfizer to investigate the potential identification and validation of a novel treatment concept for a rare bone disease.
The collaboration will utilize Sirana’s proprietary microRNA (miRNA)-targeting approach, which targets substantial regenerative recovery of diseased muscle and bone tissue.
“Combining Sirana’s novel miRNA-targeting approach, and the long-standing experience in
musculoskeletal disorders and disease mechanisms of its founders, with the expertise and
competencies of Pfizer will allow Sirana to expeditiously evaluate its drug candidates for the
treatment of this rare disease and to identify potential candidates for further development,” said Michael Kring, CEO of Sirana Pharma GmbH.
“At Pfizer, we are committed to advancing promising, emerging research – both through our
internal capabilities and through collaborations with companies like Sirana – with the goal of bringing potentially life-changing medicines to patients around the world,” said Seng H. Cheng, Ph.D., senior vice president and chief scientific officer, Pfizer Rare Disease.
“We look forward to working together with the Sirana team to further explore this new and innovative investigational approach, utilizing miRNA-targeting for the potential treatment of rare bone diseases.”